ATE180261T1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents
Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungenInfo
- Publication number
- ATE180261T1 ATE180261T1 AT91903010T AT91903010T ATE180261T1 AT E180261 T1 ATE180261 T1 AT E180261T1 AT 91903010 T AT91903010 T AT 91903010T AT 91903010 T AT91903010 T AT 91903010T AT E180261 T1 ATE180261 T1 AT E180261T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- pharmaceutical
- human lymphocytes
- dna coding
- biological uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000126A FR2656800B1 (fr) | 1990-01-08 | 1990-01-08 | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE180261T1 true ATE180261T1 (de) | 1999-06-15 |
Family
ID=9392569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91903010T ATE180261T1 (de) | 1990-01-08 | 1991-01-08 | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5773578A (de) |
| EP (1) | EP0510079B1 (de) |
| JP (1) | JP2997053B2 (de) |
| AT (1) | ATE180261T1 (de) |
| DE (1) | DE69131249T2 (de) |
| DK (1) | DK0510079T3 (de) |
| ES (1) | ES2134770T3 (de) |
| FR (1) | FR2656800B1 (de) |
| GR (1) | GR3030811T3 (de) |
| IL (1) | IL96907A (de) |
| MX (1) | MX9203379A (de) |
| WO (1) | WO1991010682A1 (de) |
| ZA (1) | ZA91134B (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316920A (en) * | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| PT758383E (pt) * | 1994-05-06 | 2007-05-31 | Roussy Inst Gustave | Fracções polipeptídicas solúveis da ptroteína lag-3; processo de produção; composição terapêutica; anticorpos anti-idiotipo |
| AU755030B2 (en) * | 1994-05-06 | 2002-11-28 | Institut Gustave Roussy | LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody |
| DE69624824T2 (de) | 1995-07-21 | 2003-09-11 | Applied Research Systems Ars Holding N.V., Curacao | Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein |
| US6500422B2 (en) * | 1996-11-29 | 2002-12-31 | Applied Research Systems Ars Holding N.V. | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3) |
| EP0900841A1 (de) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Spleissvarianten von LAG-3 |
| EP0893507A1 (de) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs |
| JP2002534961A (ja) * | 1998-12-18 | 2002-10-22 | インサイト・ファーマスーティカルズ・インコーポレイテッド | リンパ球膜タンパク質 |
| SE0103423D0 (sv) * | 2001-10-12 | 2001-10-12 | Astrazeneca Ab | Polymorphism |
| US20040258678A1 (en) * | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PL1897548T5 (pl) * | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| KR100808925B1 (ko) | 2006-09-29 | 2008-03-03 | 고려대학교 산학협력단 | 돼지 ｌａｇ-3 융합 이뮤노글로블린 |
| EP2044949A1 (de) | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| PT3508502T (pt) | 2013-09-20 | 2023-06-22 | Bristol Myers Squibb Co | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| US9683048B2 (en) | 2014-01-24 | 2017-06-20 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| JP6576962B2 (ja) | 2014-03-14 | 2019-09-18 | ノバルティス アーゲー | Ｌａｇ−３に対する抗体分子およびその使用 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| PL3169341T3 (pl) | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| MA58293B1 (fr) | 2015-07-30 | 2024-11-29 | Macrogenics, Inc. | Molécules de liaison pd-1 et leurs procédés d'utilisation |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
| CN108778301A (zh) | 2016-03-10 | 2018-11-09 | 永恒生物科技股份有限公司 | 通过联合疗法来治疗实体瘤或淋巴瘤的方法 |
| JP7167041B2 (ja) | 2017-02-10 | 2022-11-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 |
| AU2018254626B2 (en) | 2017-04-21 | 2023-12-21 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| PL3631454T3 (pl) | 2017-05-30 | 2024-01-29 | Bristol-Myers Squibb Company | Leczenie guzów lag-3 pozytywnych |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| BR112021019178A2 (pt) | 2019-03-29 | 2021-12-07 | Centre Nat Rech Scient | Variantes de interleucina-2 com atividade biológica modificada |
| WO2020232019A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| WO2021078910A1 (en) | 2019-10-22 | 2021-04-29 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| EP3824954A1 (de) | 2019-11-22 | 2021-05-26 | Centre National de la Recherche Scientifique | Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie |
| WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| AU2021275489A1 (en) | 2020-05-20 | 2022-12-01 | Centre National De La Recherche Scientifique - Cnrs - | Single domain antibodies and their use in cancer therapies |
| WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
| CA3196243A1 (en) | 2020-10-20 | 2022-04-28 | Angela Marinetti | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer |
| IL301907A (en) | 2020-10-23 | 2023-06-01 | Bristol Myers Squibb Co | LAG-3 antagonist therapy for lung cancer |
| US20230416196A1 (en) | 2020-11-18 | 2023-12-28 | Institut Curie | Dimer of biguanidines and their therapeutic uses |
| JP2024505428A (ja) | 2021-01-14 | 2024-02-06 | アンスティテュ キュリー | Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ |
| WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
| EP4337763A1 (de) | 2021-05-10 | 2024-03-20 | Institut Curie | Verfahren zur behandlung von krebs, entzündlichen erkrankungen und autoimmunerkrankungen |
| WO2023011879A1 (en) | 2021-08-05 | 2023-02-09 | Institut Curie | Scanning dynamic device for minibeams production |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| US20250019708A1 (en) | 2021-11-19 | 2025-01-16 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| JP2025510795A (ja) | 2022-03-24 | 2025-04-15 | アンスティテュ・クリー | 神経膠芽腫における腫瘍転位因子由来のネオ抗原ペプチドを標的化する免疫療法 |
| US20250213614A1 (en) | 2022-03-31 | 2025-07-03 | Institut Curie | Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression |
| WO2023194607A1 (en) | 2022-04-07 | 2023-10-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
| US20250241949A1 (en) | 2022-04-07 | 2025-07-31 | Institut Curie | Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy |
| EP4593868A1 (de) | 2022-09-26 | 2025-08-06 | Institut Curie | Myeloidzellen zur expression von il-2 und verwendungen davon zur schnellen antikrebstherapie |
| AU2024234840A1 (en) | 2023-03-13 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
| WO2024194401A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Vps4b inhibitor for use in methods for the treatment of hrd cancer |
| WO2024194402A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer |
| WO2024194673A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Methods for the treatment of dedifferentiated liposarcoma |
| WO2024213782A1 (en) | 2023-04-13 | 2024-10-17 | Institut Curie | Methods for the treatment of t-cell acute lymphoblastic leukemia |
| WO2025068393A1 (en) | 2023-09-27 | 2025-04-03 | Institut Curie | Methods for the treatment of fibrotic related diseases |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| EP4574165A1 (de) | 2023-12-21 | 2025-06-25 | Egle Therapeutics | Immunozytokine zur krebsbehandlung |
| WO2025133175A1 (en) | 2023-12-21 | 2025-06-26 | Egle Therapeutics | Immunocytokine for cancer treatment |
| WO2025158077A1 (en) | 2024-01-26 | 2025-07-31 | Institut Curie | Lipid degraders to trigger ferroptosis in cancer |
| WO2025202450A1 (en) | 2024-03-28 | 2025-10-02 | Institut Curie | Myeloid cells modified by cytokine chimeric receptor and uses thereof |
| EP4624494A1 (de) | 2024-03-29 | 2025-10-01 | Institut Curie | Her2-einzeldomänenantikörper und verwendungen davon |
| WO2025210252A1 (en) | 2024-04-05 | 2025-10-09 | Institut Curie | Modulators of fam118b protein for use in therapy |
| EP4681780A1 (de) | 2024-07-18 | 2026-01-21 | Egle Therapeutics | Immunozytokine zur krebsbehandlung |
| WO2026017820A1 (en) | 2024-07-18 | 2026-01-22 | Egle Therapeutics | Fusion protein for cancer treatment |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| EP4707295A1 (de) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2-varianten mit modifizierter biologischer aktivität |
| EP4707296A1 (de) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2-varianten mit modifizierter biologischer aktivität |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
| US4994369A (en) * | 1987-12-15 | 1991-02-19 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | T-cell activation related gene |
| US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
-
1990
- 1990-01-08 FR FR9000126A patent/FR2656800B1/fr not_active Expired - Lifetime
-
1991
- 1991-01-08 JP JP3503112A patent/JP2997053B2/ja not_active Expired - Fee Related
- 1991-01-08 ES ES91903010T patent/ES2134770T3/es not_active Expired - Lifetime
- 1991-01-08 DE DE69131249T patent/DE69131249T2/de not_active Expired - Fee Related
- 1991-01-08 WO PCT/FR1991/000009 patent/WO1991010682A1/fr not_active Ceased
- 1991-01-08 DK DK91903010T patent/DK0510079T3/da active
- 1991-01-08 MX MX9203379A patent/MX9203379A/es unknown
- 1991-01-08 EP EP91903010A patent/EP0510079B1/de not_active Expired - Lifetime
- 1991-01-08 AT AT91903010T patent/ATE180261T1/de not_active IP Right Cessation
- 1991-01-08 IL IL9690791A patent/IL96907A/en not_active IP Right Cessation
- 1991-01-08 ZA ZA91134A patent/ZA91134B/xx unknown
-
1995
- 1995-04-04 US US08/416,478 patent/US5773578A/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,988 patent/US5874250A/en not_active Expired - Lifetime
-
1999
- 1999-07-20 GR GR990401899T patent/GR3030811T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2134770T3 (es) | 1999-10-16 |
| WO1991010682A1 (fr) | 1991-07-25 |
| GR3030811T3 (en) | 1999-11-30 |
| EP0510079A1 (de) | 1992-10-28 |
| DE69131249T2 (de) | 1999-12-30 |
| DK0510079T3 (da) | 1999-11-29 |
| ZA91134B (en) | 1992-08-26 |
| MX9203379A (es) | 1992-09-01 |
| EP0510079B1 (de) | 1999-05-19 |
| IL96907A0 (en) | 1992-03-29 |
| US5773578A (en) | 1998-06-30 |
| US5874250A (en) | 1999-02-23 |
| DE69131249D1 (de) | 1999-06-24 |
| JPH05503520A (ja) | 1993-06-10 |
| FR2656800B1 (fr) | 1992-05-15 |
| FR2656800A1 (fr) | 1991-07-12 |
| IL96907A (en) | 1998-10-30 |
| JP2997053B2 (ja) | 2000-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE180261T1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
| ES2142953T3 (es) | Factor de crecimiento y diferenciacion de la familia del tgf-beta. | |
| FI963101A7 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut | |
| ITTO950367A0 (it) | Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti. | |
| AU3310595A (en) | Compositions and methods for identifying biologically active molecules | |
| NO971875L (no) | Cathepsin 02 protease | |
| FR2661187B1 (fr) | Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue. | |
| NO891805L (no) | Flertrinns biologisk renseanlegg. | |
| DE69728897D1 (de) | Saeugetierchemokine | |
| DE69836333D1 (de) | Neisseria lactoferrin-bindendes protein | |
| ATE278781T1 (de) | Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung | |
| DE68912536D1 (de) | Flüssiges Nahrungsmittel zur Proteinzuführung. | |
| FI902803A7 (fi) | DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä | |
| KR950700988A (ko) | 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof) | |
| DE59611307D1 (de) | Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln | |
| PT676413E (pt) | Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao | |
| AU4981093A (en) | Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof | |
| NO905496D0 (no) | Biologisk forenelige, stoff-spesifikke reagenser til behandling av fysiologiske vaesker. | |
| EA199800959A1 (ru) | ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ | |
| EP0780472A3 (de) | Stress Proteine | |
| DE3880486D1 (de) | Aspirator zur aufnahme von koerperfluessigkeiten. | |
| FI885025A0 (fi) | Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning. | |
| ATE309371T1 (de) | Protein mit dnase-aktivität | |
| DE69033553D1 (de) | Rekombinante herstellung von laktoperoxidase | |
| EP0854186A3 (de) | Zellteilungs-Gen DivIB von Staphylococcus aureus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |